Dr. William L. Cooper
Internal Medicine (Internal Medicine Physician)
119 W Hill St
Thomasville, GA 31792
Who else practices at this address →
Thomas County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of South Alabama College of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 676
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of South Alabama College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
GA license 045191
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Archbold Memorial Hospital Thomasville, GA
- Colquitt Regional Medical Center Moultrie, GA
Medical groups
- Select Rehabilitation, LLC (2,046 clinicians)
- Privia Medical Group of Georgia LLC (462 clinicians)
- John D Archbold Memorial Hospital Inc (61 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 676
- Services billed
- 18,107
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 915 | 373 |
| Established patient office or other outpatient visit, 20-29 minutes | 785 | 358 |
| Blood test, lipids (cholesterol and triglycerides) | 562 | 330 |
| Established patient office or other outpatient visit, 30-39 minutes | 549 | 251 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 498 | 336 |
| Blood test, comprehensive group of blood chemicals | 429 | 325 |
| Blood test, basic group of blood chemicals (calcium, total) | 330 | 182 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 329 | 329 |
| Annual depression screening, 5 to 15 minutes | 324 | 324 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 299 | 258 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 12 payments worth $208 in total to this clinician.
| Pfizer Inc. | $65.77 |
|---|---|
| Lilly USA, LLC | $45.49 |
| GlaxoSmithKline, LLC. | $31.40 |
| Leo Pharma Inc. | $26.66 |
| Novo Nordisk Inc | $18.36 |
| Amgen Inc. | $13.65 |
| Phathom Pharmaceuticals, Inc. | $6.84 |
| Food and Beverage | $208 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $431,895 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - CT-388-104 OW/OB with T2D
Genentech, Inc. - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc. - CIP341 IMPACT2
Medtronic, Inc. - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.